Hypoxic Isolated Abdominal Perfusion (HAP) chemotherapy for non-operable advanced staged ovarian cancer with peritoneal carcinosis: an experience in 45 platinum-refractory ovarian cancer patients

@inproceedings{Aigner2019HypoxicIA,
  title={Hypoxic Isolated Abdominal Perfusion (HAP) chemotherapy for non-operable advanced staged ovarian cancer with peritoneal carcinosis: an experience in 45 platinum-refractory ovarian cancer patients},
  author={Kornelia Aigner and Emir Selak and Sabine Gailhofer},
  booktitle={Indian Journal of Surgical Oncology},
  year={2019}
}
In order to break through drug resistance in platinum-refractory ovarian cancer, augmented drug exposure was administered to the abdomen by means of an isolated perfusion system. Four cycles of isolated hypoxic abdominal perfusion with cisplatin, adriamycin, and mitomycin were conducted in 4-week intervals. Cisplatin and adriamycin were chosen because of their increased cytotoxicity under hypoxic conditions. Chemofiltration was performed for prophylaxis of cumulative toxicity of adriamycin and… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 41 REFERENCES

Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016

Vanderstichele A (2016) How to select neoadjuvant chemotherapy or primary debulking surgery in patients with stage IIIC or IVovarian carcinoma

I Vergote, E Van Nieuwenhuysen
  • J Clin Oncol
  • 2016

Guidelines and evidence-based medicine – evidence of what? EJCMO 4:(3)

KR Aigner, FO Stephens
  • Available at: http:// www.slmoncology.com/Guidelines_and_Evidence_Based_ Medicine_Evidence_of_What_,1,272.html. Accessed Sept
  • 2012
VIEW 1 EXCERPT